Over the past 1 month, our portfolio companies have had great progress. See below for some of the exciting highlights.
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting
Cybrexa Therapeutics, invested and incubated by Viva BioInnovator, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics, announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex™-exatecan) on 26th Oct. The initial data show robust efficacy signals and tolerability in patients with metastatic cancer. These data also serve as a key demonstration of mechanism for Cybrexa’s antigen-independent PDC tumor targeting platform, alphalex™. Cybrexa intends to investigate CBX-12 in patients with breast, ovarian and non-small cell lung cancer.
Anji Pharma Fully Enrolls Cohort at Leading Beijing Hospital to Ready Global ANJ900 Pivotal Program in Asia
Anji Pharma (“Anji”), an emerging global medicines company invested and incubated by Viva BioInnovator, announced full enrollment for a confirmatory study in Chinese healthy participants for a delayed-release formulation of metformin called ANJ900 on 30th Nov. The Beijing study will determine whether ANJ900 can deliver metformin without exceeding the threshold of safe metformin exposure in plasma, which potentially could provide millions of chronic kidney patients with Type 2 diabetes (CKD/T2D) a treatment option where metformin is currently contraindicated. Anji plans to report topline data from this study in January 2022.
CDE Approved IND application of Genhouse for its SHP2 inhibitor GH21
On November 11th 2021, Genhouse Bio, invested and incubated by Viva BioInnovator, a biotech company focusing on development of next-generation small molecule anti-cancer therapeutics, announced today that the Center for Drug Evaluation (CDE) has recently approved IND application for Class I new drug GH21. The U.S. IND application for GH21, submitted by Genhouse’s strategic partner HUYABIO, has also been approved by FDA in October. GH21 has now received IND approval in both China and the U.S.
Fuse Biotherapeutics Secured an Oversubscribed and Upsized $9.5 Million Seed Round
Fuse Biotherapeutics, a company focused on developing next generation immune modulating therapeutics that directs and potentiates both innate and adaptive immunity, invested and incubated by Viva BioInnovator, announced it has secured an oversubscribed and upsized $9.5 million Seed round on 15th Nov. The round was led by Viva BioInnovator, the specialized investment and incubation arm of Viva Biotech. Also participating were Sherpa Healthcare Partners, Ivy Venture Group, Sirona Capital, and GC&H Investments. Proceeds from this financing will support the development of the Company's proprietary platform, which leverages the inherent capacity of NK cells to distinguish between normal and diseased tissues.
Deka Biosciences Raises USD 20 Million in Series A Financing
Maryland-based biotech company Deka Biosciences ("Deka"), announced that it has successfully closed a USD 20 Million Series A financing with a syndicate of life science investors led by Leaps by Bayer, the impact investment arm of Bayer AG, and new investor Lumira Ventures on 16th Nov. Additional investors include O-Bio (Echo Investment Capital), Viva BioInnovator, and Alexandria Venture Investments.
Eubulus Biotherapeutics and Coherent Biopharma Reached a Strategic Collaboration Agreement, To Jointly Develop Targeted Protein Degradation Drugs
Eubulus Biotherapeutics, a biotech start-up company invested and incubated by Viva BioInnovator, announced a strategic collaboration agreement with Coherent Biopharma. Eubulus has licensed out its dual-targeted protein degradation molecule developed on the TED platform to Coherent Biopharma.
ABM Therapeutics Received IND Approval in China for BRAF Inhibitor ABM-1310
ABM Therapeutics (ABM), invested and incubated by Viva BioInnovator, a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastases announced that its IND application for ABM-1310, a new-generation BRAF inhibitor has been approved by the National Medical Products Administration (NMPA) to conduct Phase 1 clinical trials in patients of advanced solid tumors with BRAF mutation in China on 30th Nov. This is the first clinical candidate and IND approval obtained by ABM Therapeutics in China.